Brief Description
This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).
Estimated Enrollment
80
Estimated End Date
8-15-2026
Trial is for people with
This clinical trial is recruiting children and young people between 2 and 25 years of age with idiopathic nephrotic syndrome that ...
Study Goal
The purpose of this clinical trial is to compare the effects of obinutuzumab in comparison to MMF in people with childhood-onset ...
What is involved for the patient?
During a ‘52 Week Treatment Period’ participants will be given the clinical trial treatment (obinutuzumab or MMF) for 52 weeks (around ...